1st Trimester Preeclampsia Screen

This test is a screening test for the development of preeclampsia prior to 34 weeks of pregnancy.

For test inquiries, call CMBP genetic services at 800-345-4363. Client must provide a fetal nuchal translucency (NT) measurement and crown rump length (CRL) measurement. The NT measurement must be performed by a sonographer credentialed by the Fetal Medicine Foundation or other equivalent entity. The sonographer's credential/certification number must be provided. 

The following information must also be provided: patient's weight and height, patient's date of birth, four blood pressure measurements (two from each arm) or mean arterial pressure, uterine artery pulsatility index (UtAPI) and number of fetuses. Also indicate relevant patient history (i.e., prior history of preeclampsia, diabetes, smoking status). Serum testing is provided from 11.0 to 14.0 weeks gestation. NT can be assessed when the CRL is 45 to 84 mm.

This is a screening test for preeclampsia to classify patients as low or high risk to develop preeclampsia later in pregnancy. 

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

Fluoroimmunometric assay

Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018 Jun;51(6):743-750. PubMed 29536574